Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance A171301)

Aminah Jatoi, Hyman Muss, Jake B. Allred, Harvey J. Cohen, Karla Ballman, Judith O. Hopkins, Ajeet Gajra, Jacqueline Lafky, Antonio Wolff, Lisa Kottschade, Julie Gralow, Arti Hurria

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Studies point to a direct association between social support and better cancer outcomes. This study examined whether baseline social support is associated with better survival and fewer chemotherapy-related adverse events in older, early-stage breast cancer patients. Methods: This study is a pre-planned secondary analysis of CALGB 49907/Alliance A171301, a randomized trial that compared standard adjuvant chemotherapy versus capecitabine in breast cancer patients 65 years of age or older. A subset reported on the extent of their social support with questionnaires that were completed 6 times over 2 years. Results: The median age of this 331-patient cohort was 72 years (range: 65, 90); 179 (55%) were married, and 210 (65%) lived with someone. One hundred forty-five patients (46%) described a social network of 0-10 people; 110 (35%) of 11-25; and 58 (19%) of 26 or more. The Medical Outcomes Study (MOS) social support survey revealed that the median scores (range) for emotional/informational, tangible, positive social interaction, and affectionate social support were 94 (3, 100), 94 (0, 100), 96 (0, 100), and 100 (8, 100), respectively. Social support scores appeared stable over 2 years and higher (more support) than in other cancer settings. No statistically significant associations were observed between social support and survival and adverse events in multivariate analyses. However, married patients had smaller tumors, and those with arthritis reported less social support. Conclusion: Although social support did not predict survival and adverse events, the exploratory but plausible inverse associations with larger tumors and arthritis suggest that social support merits further study.

Original languageEnglish (US)
JournalPsycho-Oncology
DOIs
StateAccepted/In press - 2015

Fingerprint

Social Support
Breast Neoplasms
Arthritis
Survival
Neoplasms
Adjuvant Chemotherapy
Interpersonal Relations
Multivariate Analysis
Outcome Assessment (Health Care)
Drug Therapy

Keywords

  • Breast cancer
  • Cancer
  • Older patients
  • Oncology
  • Social support

ASJC Scopus subject areas

  • Oncology
  • Psychiatry and Mental health
  • Experimental and Cognitive Psychology

Cite this

Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance A171301). / Jatoi, Aminah; Muss, Hyman; Allred, Jake B.; Cohen, Harvey J.; Ballman, Karla; Hopkins, Judith O.; Gajra, Ajeet; Lafky, Jacqueline; Wolff, Antonio; Kottschade, Lisa; Gralow, Julie; Hurria, Arti.

In: Psycho-Oncology, 2015.

Research output: Contribution to journalArticle

Jatoi, A, Muss, H, Allred, JB, Cohen, HJ, Ballman, K, Hopkins, JO, Gajra, A, Lafky, J, Wolff, A, Kottschade, L, Gralow, J & Hurria, A 2015, 'Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance A171301)', Psycho-Oncology. https://doi.org/10.1002/pon.3850
Jatoi, Aminah ; Muss, Hyman ; Allred, Jake B. ; Cohen, Harvey J. ; Ballman, Karla ; Hopkins, Judith O. ; Gajra, Ajeet ; Lafky, Jacqueline ; Wolff, Antonio ; Kottschade, Lisa ; Gralow, Julie ; Hurria, Arti. / Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance A171301). In: Psycho-Oncology. 2015.
@article{c08d465bd2f34fb6b92e9d4ac72b7a3c,
title = "Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance A171301)",
abstract = "Background: Studies point to a direct association between social support and better cancer outcomes. This study examined whether baseline social support is associated with better survival and fewer chemotherapy-related adverse events in older, early-stage breast cancer patients. Methods: This study is a pre-planned secondary analysis of CALGB 49907/Alliance A171301, a randomized trial that compared standard adjuvant chemotherapy versus capecitabine in breast cancer patients 65 years of age or older. A subset reported on the extent of their social support with questionnaires that were completed 6 times over 2 years. Results: The median age of this 331-patient cohort was 72 years (range: 65, 90); 179 (55{\%}) were married, and 210 (65{\%}) lived with someone. One hundred forty-five patients (46{\%}) described a social network of 0-10 people; 110 (35{\%}) of 11-25; and 58 (19{\%}) of 26 or more. The Medical Outcomes Study (MOS) social support survey revealed that the median scores (range) for emotional/informational, tangible, positive social interaction, and affectionate social support were 94 (3, 100), 94 (0, 100), 96 (0, 100), and 100 (8, 100), respectively. Social support scores appeared stable over 2 years and higher (more support) than in other cancer settings. No statistically significant associations were observed between social support and survival and adverse events in multivariate analyses. However, married patients had smaller tumors, and those with arthritis reported less social support. Conclusion: Although social support did not predict survival and adverse events, the exploratory but plausible inverse associations with larger tumors and arthritis suggest that social support merits further study.",
keywords = "Breast cancer, Cancer, Older patients, Oncology, Social support",
author = "Aminah Jatoi and Hyman Muss and Allred, {Jake B.} and Cohen, {Harvey J.} and Karla Ballman and Hopkins, {Judith O.} and Ajeet Gajra and Jacqueline Lafky and Antonio Wolff and Lisa Kottschade and Julie Gralow and Arti Hurria",
year = "2015",
doi = "10.1002/pon.3850",
language = "English (US)",
journal = "Psycho-Oncology",
issn = "1057-9249",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance A171301)

AU - Jatoi, Aminah

AU - Muss, Hyman

AU - Allred, Jake B.

AU - Cohen, Harvey J.

AU - Ballman, Karla

AU - Hopkins, Judith O.

AU - Gajra, Ajeet

AU - Lafky, Jacqueline

AU - Wolff, Antonio

AU - Kottschade, Lisa

AU - Gralow, Julie

AU - Hurria, Arti

PY - 2015

Y1 - 2015

N2 - Background: Studies point to a direct association between social support and better cancer outcomes. This study examined whether baseline social support is associated with better survival and fewer chemotherapy-related adverse events in older, early-stage breast cancer patients. Methods: This study is a pre-planned secondary analysis of CALGB 49907/Alliance A171301, a randomized trial that compared standard adjuvant chemotherapy versus capecitabine in breast cancer patients 65 years of age or older. A subset reported on the extent of their social support with questionnaires that were completed 6 times over 2 years. Results: The median age of this 331-patient cohort was 72 years (range: 65, 90); 179 (55%) were married, and 210 (65%) lived with someone. One hundred forty-five patients (46%) described a social network of 0-10 people; 110 (35%) of 11-25; and 58 (19%) of 26 or more. The Medical Outcomes Study (MOS) social support survey revealed that the median scores (range) for emotional/informational, tangible, positive social interaction, and affectionate social support were 94 (3, 100), 94 (0, 100), 96 (0, 100), and 100 (8, 100), respectively. Social support scores appeared stable over 2 years and higher (more support) than in other cancer settings. No statistically significant associations were observed between social support and survival and adverse events in multivariate analyses. However, married patients had smaller tumors, and those with arthritis reported less social support. Conclusion: Although social support did not predict survival and adverse events, the exploratory but plausible inverse associations with larger tumors and arthritis suggest that social support merits further study.

AB - Background: Studies point to a direct association between social support and better cancer outcomes. This study examined whether baseline social support is associated with better survival and fewer chemotherapy-related adverse events in older, early-stage breast cancer patients. Methods: This study is a pre-planned secondary analysis of CALGB 49907/Alliance A171301, a randomized trial that compared standard adjuvant chemotherapy versus capecitabine in breast cancer patients 65 years of age or older. A subset reported on the extent of their social support with questionnaires that were completed 6 times over 2 years. Results: The median age of this 331-patient cohort was 72 years (range: 65, 90); 179 (55%) were married, and 210 (65%) lived with someone. One hundred forty-five patients (46%) described a social network of 0-10 people; 110 (35%) of 11-25; and 58 (19%) of 26 or more. The Medical Outcomes Study (MOS) social support survey revealed that the median scores (range) for emotional/informational, tangible, positive social interaction, and affectionate social support were 94 (3, 100), 94 (0, 100), 96 (0, 100), and 100 (8, 100), respectively. Social support scores appeared stable over 2 years and higher (more support) than in other cancer settings. No statistically significant associations were observed between social support and survival and adverse events in multivariate analyses. However, married patients had smaller tumors, and those with arthritis reported less social support. Conclusion: Although social support did not predict survival and adverse events, the exploratory but plausible inverse associations with larger tumors and arthritis suggest that social support merits further study.

KW - Breast cancer

KW - Cancer

KW - Older patients

KW - Oncology

KW - Social support

UR - http://www.scopus.com/inward/record.url?scp=84929833122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929833122&partnerID=8YFLogxK

U2 - 10.1002/pon.3850

DO - 10.1002/pon.3850

M3 - Article

C2 - 25994447

AN - SCOPUS:84929833122

JO - Psycho-Oncology

JF - Psycho-Oncology

SN - 1057-9249

ER -